11 April 2008 – Cancer drug developer
Antisoma plc (LSE: ASM; US OTC: ATSMY) announces that its partner
Novartis has started the pivotal phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for marketing authorisations in the US, Europe and other territories.
Its initiation triggers a USD 25 million milestone payment to Antisoma...
Antisoma's Press Release -
Novartis' Press Release -
